WARSAW — Nextremity Solutions, Inc., a Strategic Commercialization Organization in the musculoskeletal space, located in Warsaw, “The Orthopedic Capital of the World,” announced that it has achieved record setting revenue for the first half of 2017.

Nextremity Solutions believes that the successes the Company is seeing are directly tied to its surgeon-driven i3^TM Strategic Solutions product development strategy, as well as its distribution agreement with a worldwide strategic partner. In October, Nextremity Solutions announced it had finalized an exclusive global distribution agreement for its first four commercialized products, which address unmet clinical needs in forefoot elective surgery.

“Our i3 Strategic Solutions product development pipeline in the foot and ankle space remains strong and the company will begin to expand into other markets in 2018. Nextremity Solutions’ team remains very excited as we continue to take the next steps to expand our product development portfolio and continue to pursue our mission of becoming recognized as the premier musculoskeletal Strategic Commercialization Organization. We have an amazing group of talented professionals who are passionate about creating innovative technology and solutions that advance the standard of care for surgeons and patients worldwide,” stated Ryan Schlotterback, chief commercial officer for Nextremity Solutions.

“The Company continues to be EBITDA positive as it heads into its second half of 2017 and is on track to achieve annual revenue forecasts. Our recent financial performance is the result of our team’s hard work and dedication. Because of our mutually beneficial relationship with our strategic alliance partner, our team can focus strongly on our i3 Strategic Solutions strategy and continue to produce Revenue Ready^TM products and solutions that are beneficial to surgeons and patients worldwide,” commented Rod K. Mayer, president and CEO of Nextremity Solutions.

Nextremity Solutions, recently announced the limited release of its newest product, the PiroVue^TM Gastrocnemius Recession System for the treatment of equinus deformities in patients and plans to announce the limited release of yet another new product in Q4 2017.